JP7839786B2 - 新規アミノピリジン及びその癌治療への使用 - Google Patents

新規アミノピリジン及びその癌治療への使用

Info

Publication number
JP7839786B2
JP7839786B2 JP2023518938A JP2023518938A JP7839786B2 JP 7839786 B2 JP7839786 B2 JP 7839786B2 JP 2023518938 A JP2023518938 A JP 2023518938A JP 2023518938 A JP2023518938 A JP 2023518938A JP 7839786 B2 JP7839786 B2 JP 7839786B2
Authority
JP
Japan
Prior art keywords
nhr
alkyl
nhc
halo
cho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023518938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542548A (ja
JP2023542548A5 (https=
Inventor
ディクソン，ベンジャミン・ディー
ヘイ，マイケル・パトリック
ホン，チョ・ロン
ワン，ウェイ・フア
ウィルソン，ウィリアム・ロバート
リュウ，リディア・ピエン・ピン
ジェイミソン，スティーブン・マイケル・フレイザー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of JP2023542548A publication Critical patent/JP2023542548A/ja
Publication of JP2023542548A5 publication Critical patent/JP2023542548A5/ja
Application granted granted Critical
Publication of JP7839786B2 publication Critical patent/JP7839786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023518938A 2020-09-24 2021-09-24 新規アミノピリジン及びその癌治療への使用 Active JP7839786B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ768245 2020-09-24
NZ76824520 2020-09-24
PCT/IB2021/058707 WO2022064430A1 (en) 2020-09-24 2021-09-24 Novel aminopyridines and their use in treating cancer

Publications (3)

Publication Number Publication Date
JP2023542548A JP2023542548A (ja) 2023-10-10
JP2023542548A5 JP2023542548A5 (https=) 2025-08-14
JP7839786B2 true JP7839786B2 (ja) 2026-04-02

Family

ID=80844550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518938A Active JP7839786B2 (ja) 2020-09-24 2021-09-24 新規アミノピリジン及びその癌治療への使用

Country Status (7)

Country Link
US (1) US20230365559A1 (https=)
EP (1) EP4217357A4 (https=)
JP (1) JP7839786B2 (https=)
CN (1) CN116669725A (https=)
AU (1) AU2021346954A1 (https=)
CA (1) CA3192868A1 (https=)
WO (1) WO2022064430A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
JP2026509874A (ja) * 2023-03-13 2026-03-25 インサイト・コーポレイション キナーゼ阻害剤としての二環式尿素

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238929A1 (en) 2018-06-15 2019-12-19 Astrazeneca Ab Purinone compounds and their use in treating cancer
JP2020504107A (ja) 2016-12-20 2020-02-06 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用
JP2020521771A (ja) 2017-05-26 2020-07-27 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ ベンズイミダゾロン由来のｂｃｌ６阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
CA2902858A1 (en) * 2013-02-28 2014-09-04 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
ME03336B (me) * 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
GB201819126D0 (en) * 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
WO2020140054A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020504107A (ja) 2016-12-20 2020-02-06 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用
JP2020521771A (ja) 2017-05-26 2020-07-27 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ ベンズイミダゾロン由来のｂｃｌ６阻害剤
WO2019238929A1 (en) 2018-06-15 2019-12-19 Astrazeneca Ab Purinone compounds and their use in treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIAPETTI, Paola，Molecular Variations Based on Isosteric Replacements，The Practice of Medicinal Chemistry，2008年，181-241
Goldberg, Frederick W. et al.，The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor，Journal of Medicinal Chemistry，2020年，63 (7)，3461-3471
HAY, Michael P. et al.，Synthesis and Evaluation of Nitroheterocyclic Carbamate Prodrugs for Use with Nitroreductase-Mediated Gene-Directed Enzyme Prodrug Therapy ，Journal of Medicinal Chemistry，2003年，46 (25)，5533-5545

Also Published As

Publication number Publication date
JP2023542548A (ja) 2023-10-10
WO2022064430A1 (en) 2022-03-31
EP4217357A4 (en) 2024-11-06
EP4217357A1 (en) 2023-08-02
AU2021346954A9 (en) 2024-02-08
CN116669725A (zh) 2023-08-29
CA3192868A1 (en) 2022-03-31
US20230365559A1 (en) 2023-11-16
AU2021346954A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
RU2470934C1 (ru) Новое трициклическое производное или его фармацевтически приемлемые соли, способ их получения и содержащая их фармацевтическая композиция
US11958837B2 (en) Quinazolinones as PARP14 inhibitors
CN107530329B (zh) 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物
JP5369302B2 (ja) Ｐｄｅ４阻害剤としてのピリドピリミジンジオン類
TWI393566B (zh) 作為週期素依賴性激酶之新穎吡唑并嘧啶
JP7839786B2 (ja) 新規アミノピリジン及びその癌治療への使用
JP7844707B2 (ja) 療法に使用するためのｐａｒｐ１４の標的タンパク質分解
US20240368169A1 (en) Substituted tricyclic compounds as parp inhibitors and use thereof
WO2018090939A1 (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
ES2349476T3 (es) Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
IL237840A (en) Quinazolinone history, preparation and pharmaceutical preparations containing them
JP7777596B2 (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
KR20140121477A (ko) Ｔａｎｋ 및 ｐａｒｐ 저해체로서의 테트라히드로-퀴나졸리논
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
CN115785074B (zh) Parp7抑制剂及其用途
CN105693634A (zh) 化合物及其用途
CN120917019A (zh) 噻二唑酮衍生物及其组合物和应用
WO2019043373A1 (en) SUBSTITUTED CYCLYL-SULFONAMIDES AS MODULATORS OF THE HEDGEHOG SIGNALING PATHWAY (HH)
TW202417434A (zh) 用於治療之parp14之靶向蛋白質降解
EP2017277A1 (en) Thiophene-imidazopyridines
HK1202551B (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250519

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260323

R150 Certificate of patent or registration of utility model

Ref document number: 7839786

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150